REFERENCES
- Brashear, A., Lew, M. F., Dyskstra, D. D., (1999). Safety and efficacy of Neurobloc (botulinum toxin type B) in type-A-responsive cervical dystonia. Neurology, 53(7), 1439–1446.
- Brin, M. F., Lew, M. F., Adler, C. H., (1999). Safety and efficacy of Neurobloc (botulinum toxin type B) in type-A-resistant cervical dystonia. Neurology, 53(7), 1431–1438.
- Consky, E. S., & Lang, A. E. (1994). Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York, NY: Marcel Dekker; p. 211–237.
- Lew, M. F., Germanson, T., & Pappert, E. J. (2008). Botulinum toxin type B effects on pain associated with cervical dystonia: Results of a meta-analysis. Neurology, 70(11; suppl. 1), A387–A388.
- Molho, E. S., Agarwal, N., Regan, K., Higgins, D. S., & Factor, S. A. (2009). Effect of cervical dystonia on employment: A retrospective analysis of the ability of treatment to restore premorbid employment status. Movement Disorders, 24(9), 1384–1387.
- Pappert, E. J., & Germanson, T. (2008). Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, non-inferiority trial. Movement Disorders, 23(4), 510–517.
- Skogseid, I. M., Roislien, J., Claussen, B., & Kerty, E. (2005). Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia. Movement Disorders, 20(12), 1604–1619.